Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 4:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1153–1176 of 9,516 matching trials from the live ClinicalTrials.gov search.
Filters: Birmingham, Alabama Clear all
Completed Phase 1Phase 2 Interventional

ALD-301 for Critical Limb Ischemia, Randomized Trial

NCT00392509
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Arterial Disease, Peripheral Vascular Disease
Interventions
ALDH-br bone marrow cells vs. mononuclear bone marrow cells
Procedure
Lead sponsor
Aldagen
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated May 14, 2009 · Synced Oct 21, 2026, 4:14 PM EDT
Completed No phase listed Observational

Covid Flu A/B and RSV 4 in 1 Diagnostic Test

NCT07308158
View directory record Official record
Conditions
Influenza A, Influenza B, COVID - 19, RSV
Interventions
Investigational Flu A/B Covid-19 and RSV Diagnostic Test
Diagnostic Test
Lead sponsor
iHealth Labs inc
Industry
Eligibility
6 Months and older
Enrollment
1,119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Trussville, Alabama • Dublin, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

NCT05724199
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Rocatinlimab, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
746 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City West, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Safety and Effectiveness of ADX-N05 for Excessive Daytime Sleepiness in Subjects With Narcolepsy

NCT01681121
View directory record Official record
Conditions
Narcolepsy
Interventions
ADX-N05, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Redwood City, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 28, 2021 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional

Effects of ONO-2506PO in Patients With Alzheimer's Disease

NCT00083421
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
ONO-2506PO
Drug
Lead sponsor
Ono Pharma USA Inc
Industry
Eligibility
50 Years to 90 Years
Enrollment
647 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
79
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2012 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Flibanserin Randomized Withdrawal Trial in Pre-menopausal Women

NCT00277914
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
749 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
55
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2012 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

NCT01553747
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Eluxadoline, Placebo
Drug
Lead sponsor
Furiex Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
1,146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
232
States / cities
Birmingham, Alabama • Decatur, Alabama • Huntsville, Alabama + 189 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2018 · Synced Oct 21, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional

Dose-Ranging Safety, Tolerability, and Efficacy Study of AZD2373 in Participants With APOL1-Mediated Kidney Disease

NCT06824987
View directory record Official record
Conditions
APOL1-Mediated Kidney Disease
Interventions
AZD2373-Arm 1, AZD2373-Arm 2, Placebo, APOL1 Genotyping Clinical Trial Assay
Combination Product · Device
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
86
States / cities
Alabaster, Alabama • Birmingham, Alabama • Irondale, Alabama + 73 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy Children

NCT05543616
View directory record Official record
Conditions
SARS-CoV-2 Virus, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19
Interventions
Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 6 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 3 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 6 microgram dose, Variant-adapted BNT162b2 (Omicron XBB.1.5) 10 microgram dose, Variant-adapted BNT162b2 (Omicron KP.2) 10 microgram dose
Biological
Lead sponsor
BioNTech SE
Industry
Eligibility
6 Months to 11 Years
Enrollment
4,338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
72
States / cities
Birmingham, Alabama • Phoenix, Arizona • Anaheim, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional

Bicalutamide (Casodex™) Versus Placebo in Patients With Early Prostate Cancer

NCT00657904
View directory record Official record
Conditions
Non-metastatic Prostate Cancer
Interventions
Bicalutamide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
3,618 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2008
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 21, 2026, 4:14 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

The Effects of Exogenous Ketones on Cognitive Function

NCT07051655
View directory record Official record
Conditions
Placebo - Control, Ketone Monoester
Interventions
Ketone Monoester (KE), Placebo
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 55 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Recruiting No phase listed Observational

Improving Safety and Quality of Tracheal Intubation Practice in Pediatric ICUs

NCT02493478
View directory record Official record
Conditions
Failed or Difficult Intubation, Sequela, Intubation; Difficult, Intubation Complication
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Not listed
Enrollment
150,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2030
U.S. locations
63
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Open Label Long-Term Safety Study of Certolizumab Pegol (CZP) for Patients With Rheumatoid Arthritis

NCT00160693
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
29
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Washington D.C., District of Columbia + 26 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 21, 2026, 4:14 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

ASPREE Cancer Endpoints Study

NCT01968798
View directory record Official record
Conditions
Cancer
Interventions
Aspirin, Placebo
Drug
Lead sponsor
Hennepin Healthcare Research Institute
Other
Eligibility
65 Years and older
Enrollment
14,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
40
States / cities
Birmingham, Alabama • Palo Alto, California • Washington D.C., District of Columbia + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2021 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 3 Interventional Results available

Tolvaptan Extension Study in Participants With ADPKD

NCT01214421
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Interventions
Tolvaptan
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years and older
Enrollment
1,083 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
38
States / cities
Mobile, Alabama • Peoria, Arizona • Tempe, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Phase II Pharmacokinetics Study of CAM2038

NCT02710526
View directory record Official record
Conditions
Opioid Use Disorder, Chronic Pain
Interventions
CAM2038
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
19 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Berlin, New Jersey • Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Apr 30, 2020 · Synced Oct 21, 2026, 4:14 PM EDT
Completed No phase listed Observational

Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)

NCT01591252
View directory record Official record
Conditions
HIV, Osteoporosis
Interventions
Not listed
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 21, 2026, 4:14 PM EDT
Recruiting Phase 3 Interventional

A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss

NCT05382338
View directory record Official record
Conditions
Childhood Medulloblastoma
Interventions
Audiometric Test, Auditory Brainstem Response, Biospecimen Collection, Cisplatin, Cyclophosphamide, Lomustine, Magnetic Resonance Imaging, Quality-of-Life Assessment, Radiation Therapy, Sodium Thiosulfate, Survey Administration, Vincristine
Procedure · Drug · Other + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
4 Years to 21 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
106
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 92 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Not applicable Interventional Results available

A Clinical Trial to Evaluate the HeartWare™ Ventricular Assist System (ENDURANCE SUPPLEMENTAL TRIAL)

NCT01966458
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
HeartWare® VAS (HVAD), Control LVAD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
494 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 37 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 21, 2026, 4:14 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)

NCT04195555
View directory record Official record
Conditions
Recurrent Ependymoma, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Glioma, Recurrent Malignant Solid Neoplasm, Recurrent Medulloblastoma, Recurrent Neuroblastoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent WHO Grade 2 Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Langerhans Cell Histiocytosis, Refractory Malignant Germ Cell Tumor, Refractory Malignant Glioma, Refractory Malignant Solid Neoplasm, Refractory Medulloblastoma, Refractory Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma, Refractory WHO Grade 2 Glioma, Wilms Tumor
Interventions
Ivosidenib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Months to 21 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
171
States / cities
Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 129 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 21, 2026, 4:14 PM EDT
Enrolling by invitation No phase listed Observational

Multicenter Prospective Cohort Study on Current Treatments of Legg-Calvé-Perthes Disease

NCT02040714
View directory record Official record
Conditions
Legg Calve Perthes Disease
Interventions
Osteotomy + Long Term Non-Weight Bearing, Osteotomy + Short Term Non-Weight Bearing, Nonoperative Observation, Multiple Epiphyseal Drilling
Procedure
Lead sponsor
Texas Scottish Rite Hospital for Children
Other
Eligibility
1 Year to 18 Years
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2032
U.S. locations
28
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 23 more
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 21, 2026, 4:14 PM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate the Treatment Effect of PT003 on Cardiovascular Hemodynamics in Subjects With Moderate to Severe COPD

NCT02685293
View directory record Official record
Conditions
COPD
Interventions
GFF MDI (PT003), Placebo MDI
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Phase 2 Interventional Results available

Study of Early Relapsed, Lenalidomide-refractory Subjects Eligible for Carfilzomib Triplet

NCT04191616
View directory record Official record
Conditions
Relapsed or Refractory Multiple Myeloma
Interventions
Carfilzomib, Dexamethasone, Pomalidomide
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 99 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
13
States / cities
Birmingham, Alabama • Denver, Colorado • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 21, 2026, 4:14 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Pilot Study to Determine Nutrition Status in Glioblastoma Multiforme Patients

NCT01770626
View directory record Official record
Conditions
Brain Cancer
Interventions
Nutrition
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 28, 2014 · Synced Oct 21, 2026, 4:14 PM EDT